This study evaluated the effect of DA-8159, a new phosphodiesterase 5 inhibitor, on the compensatory development of right ventricular hypertrophy in monocrotaline (MCT)-induced pulmonary hypertension (PH). Rats treated with subcutaneous MCT were divided into three groups, which received DA-8159 1 mg/kg, DA-8159 5 mg/kg or saline-vehicle orally, twice daily for 21 days. The vehicle group demonstrated increased right ventricular weight, pulmonary artery medial wall thickening, myocardial fibrosis, increased plasma cyclic guanosine monophosphate (cGMP) concentration and reduced body weight gains. DA-8159, however, markedly attenuated the compensatory development of right ventricular hypertrophy and pulmonary artery medial wall thickening, amplified the increase in plasma cGMP levels and increased lung cGMP concentrations. In addition, DA-8159 prevented myocardial fibrosis induced by MCT. These results demonstrate that DA-8159 attenuates the compensatory development of right ventricular hypertrophy in a rat model of PH. DA-8159 might, therefore, be a useful treatment option for PH, but its efficacy in humans needs evaluating. KEY WORDS: DA-8159; PHOSPHODIESTERASE 5 INHIBITOR; PULMONARY HYPERTENSION; RIGHT VENTRICULAR HYPERTROPHY KK Kang, GJ Ahn, YS Sohn et al. DA-8159 attenuates right ventricular hypertrophy KK Kang, GJ Ahn, YS Sohn et al. DA-8159 attenuates right ventricular hypertrophy •
Introduction
Primary pulmonary hypertension (PH) is a progressive disease, with a median survival rate of 2.8 years from the time of diagnosis. 1 PH is characterized by a progressive elevation in pulmonary vascular resistance, which results in an inability of the right ventricle to sustain its output and leads to right ventricular failure and death. 2 Various vasodilators (such as prostacyclin and calcium antagonists) have been used to treat PH. Continuous intravenous infusion with prostacyclin was found to reduce mortality in patients with PH by decreasing the pressure in the pulmonary arteries. 3 Use of systemic prostacyclin is, however, limited by problems with catheter infection, systemic hypotension, tachyphylaxis and a lack of selectivity for the pulmonary vasculature. Inhaled nitric oxide (NO) is a known selective pulmonary vasodilator, and is reported to be effective in PH. 4, 5 However, as problems such as potential toxicity and difficulty in ambulatory inhalation are associated with the long-term use of inhaled NO, 6 the development of an orally effective, long-lasting and well-tolerated agent for PH would prove valuable.
Nitric oxide and natriuretic peptides are important factors in regulating the vascular tone of pulmonary arteries, and their vasorelaxing action is mediated by cyclic guanosine monophosphate (cGMP). Levels of cGMP in the pulmonary vasculature can be elevated by inhibiting the phosphodiesterases (PDEs) responsible for cGMP hydrolysis in the lung. PDE5 is a major cGMP-dependent PDE subtype in the pulmonary vasculature and is more abundant in the lung than in other tissues. 7 This suggests that inhibiting PDE5 may induce pulmonary vasodilation, and thus be useful in the treatment of PH. Recently, cGMP-specific PDE5 inhibitors were shown to be potent, acute, selective pulmonary vasodilators. 2,8 -13 However, no PDE5 inhibitor has yet been approved for the treatment of PH, mainly because of their non-specific effects on other PDE subgroups and on adenosine metabolism. 14 One PDE5 inhibitor, sildenafil (either alone or combined with iloprost), was shown to reduce pulmonary artery pressure (PAP) and improve exercise capacity in patients with PH; it is now being evaluated in clinical trials. 15, 16 This suggests that PDE5 is a potential pharmacological agent for pulmonary vasodilation.
DA-8159 is a selective PDE5 inhibitor developed by the Dong-A Pharmaceutical Co. Ltd (Kyunggi, South Korea) as an oral treatment for erectile dysfunction. DA-8159 induces a penile erection in anaesthetized and conscious animals, enhances relaxation of smooth muscle, and increases endogenous cGMP levels in rabbit corpus cavernosal smooth muscles. 17 Data from a phase 1 clinical study showed that a single oral dose of up to 400 mg DA-8159 was well tolerated in healthy Asian or Caucasian males. 18 In this study, we examined the effect of long-term administration of DA-8159 on the compensatory development of right ventricular hypertrophy in a rat model of monocrotaline (MCT)-induced PH.
Materials and methods

CHEMICALS
DA-8159 (CAS No.; 268203-93-6), a pyrazolopyrimidinone derivative with a molecular weight of 516.66 Da and a melting point of 158 -161 o C, was synthesized in-house. The purity of this DA-8159 was > 99.8%, as determined by high-pressure liquid chromatography and potentiometric titrations in glacial acetic acid. DA-8159 is stable for at least 12 weeks, at both ambient temperature and under accelerated conditions (20 o C, 75% relative humidity).
The MCT (Sigma Chemical Co., St. Louis, MO, USA) was prepared by dissolving it in 1 N hydrochloric acid (HCl). The pH was neutralized with 0.5 N sodium hydroxide, and the volume of the solution adjusted with phosphate-buffered saline (pH 7.4) to achieve a concentration of 30 mg/ml. DA-8159 was dissolved in a Titrisol ® buffer solution (citrate sodium hydroxide buffer, pH 5.0; Merck, Darmstadt, Germany) for oral administration.
ANIMALS
This study was performed in accordance with the Dong-A Pharmaceutical Co. Ltd institutional standard operation procedure for animal care and experiments (SOP-ANC) and the Guide for the Care and Use of Laboratory Animals from the US National Institutes of Health.
The male Sprague-Dawley rats (Charles River Japan, Japan) were kept under standard laboratory conditions (temperature 23 ± 2 o C, humidity range 40 -70%, 12-h light/dark cycle (lighting: 07.00 -19.00) throughout the study. Rats were allowed free access to food and UV-sterilized tap water.
EXPERIMENTAL PROTOCOL
Pulmonary hypertension was induced by the administration of MCT as described previously. 19 Briefly, after acclimatization the animals were blindly randomized to receive subcutaneous MCT 60 mg/kg (n = 60) or an equal volume of saline-vehicle (n = 5). Rats treated with subcutaneous MCT were blindly randomized to three groups (n = 20), and received DA-8159 1 mg/kg, DA-8159 5 mg/kg or vehicle orally twice daily (08.00 and 20.00) for 21 days.
At the end of treatment (day 21), the rats were anaesthetized with pentobarbital, the chest and abdominal cavities opened quickly and a blood sample collected from the abdominal aorta. This was placed in a plastic tube containing 3.8% sodium citrate and centrifuged at 574 g for 5 min at 4 o C to separate the plasma. The plasma was then stored at -20 o C for the measurement of plasma cGMP concentrations.
MEASUREMENT OF HEART WEIGHT
The heart was dissected and any excess blood removed. The organs were then weighed, and the heart weight:body weight ratio calculated. The right ventricular free wall was separated from the left ventricle and the septum in order to determine the wet weight. The right ventricle weight:body weight (RV/BW), left ventricle plus the septum weight:body weight (LV + S/BW) ratios and the cardiac weight (RV + LV + S/BW) were calculated. The ratio of the right ventricle weight:left ventricle plus septum weight (RV/LV + S) was calculated to determine the index of right ventricular hypertrophy.
MYOCARDIAL MORPHOLOGY
The myocardial and lung tissues were fixed in 10% buffered formalin and embedded in paraffin for morphological analyses. Sections 5 µm in depth were stained with haematoxylin-eosin or Masson's trichrome stain, according to standard methods.
MEASUREMENT OF cGMP LEVELS IN PLASMA AND LUNG
The cGMP concentrations were measured using an enzyme immunoassay (EIA) kit (Cayman Chemical, Ann Arbor, MI, USA), according to the method reported previously, 20 and as per the manufacturer's instructions. To determine the cGMP levels in plasma, 2 ml of ice-cold ethanol were added to 500 µl of plasma, and the solution centrifuged at 1500 g for 10 min at 4 o C. The supernatant was evaporated by vacuum centrifugation (Speed Vac, Savant Instruments, Holbrook, NY, USA) and used for the cGMP measurements.
To measure the intracellular cGMP levels in the lung, the lung was dissected, frozen in liquid nitrogen and stored at -70 o C until required. Each tissue sample was homogenized in 1 ml of 0.1 N HCl. The homogenate was centrifuged at 3000 g for 10 min at 4 o C, and the supernatant evaporated using the Speed Vac method. The cGMP concentration in the residue was determined using an EIA kit, and the protein concentration of the pellet was determined using a bicinchoninic acid protein assay reagent (Pierce Chemical Co., Milwaukee, WI, USA). The cGMP level in KK Kang, GJ Ahn, YS Sohn et al.
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the lung was normalized to the quantity of protein.
MEASUREMENT OF PULMONARY ARTERY WALL THICKNESS
The medial wall thickness was measured according to the method reported previously. 19, 21 Briefly, the left lung of each animal was harvested, fixed in 10% buffered formalin and embedded in paraffin. Sections were stained with haematoxylin-eosin for light microscopy. The thickness of the medial arterial layer and the external diameter were measured in 10 randomly selected vessels from each rat. The percentage of medial wall thickness, which is an index of medial hypertrophy, was calculated using the method reported by Cassis et al. 22 and the following equation: (2 × medial thickness/ external diameter) × 100.
STATISTICAL ANALYSIS
Results are expressed as a mean ± 1 SD, and the data were analysed by a one-way analysis of variance. A P-value of < 0.05 was considered significant.
Results
BODY WEIGHT CHANGES
The initial body weight of the rats ranged from 230 -250 g. The animals treated with MCT showed a significant deceleration in body weight gain over the 21 days of follow-up. Body weight gain was lower in the DA-8159-treated groups than the saline-treated control group. However, the DA-8159-treated animals demonstrated a significant increase in body weight gains over the 21-day period compared with the MCT-treated animals ( Table 1) .
EFFECT OF DA-8159 ON RIGHT VENTRICLE TISSUE WEIGHT
The MCT group developed right ventricular and cardiac hypertrophy, and demonstrated significant increases in the RV/BW, RV + LV + S/BW and RV/LV + S ratios ( Table 2 , Fig. 1 ). Right ventricular hypertrophy and cardiac hypertrophy were improved in both the 1 mg/kg and 5 mg/kg DA-8159-treated groups, as shown by decreases in the RV/LV + S ratio (Fig. 1) , and the RV/BW and RV + LV + S/BW ratios, respectively ( Table 2 ).
MYOCARDIAL MORPHOLOGY
On staining with Masson's trichrome stain, right ventricle samples from MCT-treated animals clearly showed the presence of fibrosis. In contrast, the administration of DA-8159 attenuated the development of fibrotic changes in the right ventricle (in a dose-dependent manner). Representative micrographs are shown in Fig. 2 . 
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LEVELS OF cGMP IN PLASMA AND LUNG
Plasma cGMP levels were significantly higher in the MCT-treated group than the control group ( Fig. 3A , P < 0.05). In contrast, MCT did not influence lung cGMP levels (Fig. 3B ).
The increase in plasma cGMP levels was amplified significantly in the groups treated with 1 mg/kg and 5 mg/kg DA-8159 ( Fig. 3A , P < 0.05) compared with the MCT group. Lung 
MEDIAL WALL THICKNESS OF PULMONARY ARTERY
The effect of DA-8159 on development of MCT-induced pulmonary vascular wall thickening can be seen in Fig. 4 . MCT produced a significant increase in medial wall thickening of the pulmonary artery. However, DA-8159 significantly reduced the thickness of the medial wall (in a dose-dependent manner). Representative micrographs of the pulmonary arteries are shown in Fig. 5 .
Discussion
This study demonstrates that long-term oral It is known that cGMP plays an important role in regulating vascular smooth muscle tone, including that of the pulmonary vascular bed. Several endogenous vasodilators, such as NO and atrial natriuretic peptides, cause relaxation of vascular smooth muscle by increasing intracellular cGMP concentrations. This is achieved via activation of soluble guanylate cyclase (GC) and the subsequent activation of protein kinase G. 27 In addition to GC activity, the intracellular concentration of cGMP is determined by PDE activity, as this rapidly inactivates cGMP to GMP. 28 This means that intracellular cGMP concentrations and smooth muscle cell relaxation are governed by the balance between GC and PDE activity. 2 Among the PDE isoenzymes, PDE5 (an isoenzyme that specifically hydrolyses cGMP) is distributed abundantly in lung tissues. The activity of PDE5 is reported to be much higher in the lung than in the aortic tissue of chronically hypoxic pulmonary hypertensive rats. 29 Inhibiting this enzyme with selective inhibitors is, therefore, likely to increase levels of cGMP in lung tissue and to cause pulmonary vasodilation. Indeed, previous studies have shown that selective PDE5 inhibitors produce pulmonary vasodilation and attenuate the development of PH in animal models. 2, 8, 13 Dipyridamole and zaprinast (AG Scientific Inc., San Diego, CA, USA) have been shown to attenuate hypoxia-induced pulmonary vasoconstriction and remodelling, 30 -32 but their clinical use is limited by their lack of selectivity. The selective PDE5 inhibitors, E4021 and E4010, have been reported to reduce PAP in animal models, but these drugs are not available for use in humans. 2, 8, 33, 34 More recently, sildenafil -an orally active inhibitor of PDE5 used to treat erectile dysfunction -has been shown to produce a dose-dependent reduction in PAP in animal studies and in clinical trials in humans. 11, 13 It has not yet been approved for clinical use. This study used a novel selective PDE5 inhibitor, DA-8159. The IC 50 value for PDE5 is 5 ng/ml, which is comparable to that of sildenafil. The half-life of DA-8159 in people of Asian and Caucasian origin, however, is approximately 10 h and 13 h, respectively, which is much longer than the half-life of sildenafil. 18 The primary goal of this study was to evaluate the potential contribution of DA-8159 to the compensatory development of myocardial hypertrophy and the subsequent responses occurring in rats with MCT-induced PH. Weight gain, which was greatly reduced after MCT treatment, 8 was significantly increased in the DA-8159treated groups compared with the MCT group. These results demonstrate that animals treated with DA-8159 fared better than their untreated (control) counterparts, suggesting a marked reduction in mortality in these animals (data not shown). DA-8159 attenuated the MCT-induced right ventricular hypertrophy, which is believed to result from an increased pulmonary vascular tone. In addition, medial wall thickness in the pulmonary arteries was reduced in DA-8159-treated animals.
Although the mechanism responsible for the effects of DA-8159 is unclear, its pulmonary vasodilating effect (via increasing cGMP levels in smooth muscles) is believed to contribute, at least in part, to the prevention of right ventricular hypertrophy and medial wall thickening. In this study, DA-8159 increased cGMP levels both in plasma and in the lungs. Considering the specific inhibitory activity of DA-8159 on PDE5, these results suggest that chronic treatment with a selective PDE5 inhibitor can preferentially decrease the rate of cGMP degradation. Such treatment could also increase the intracellular cGMP concentration in lung tissue due to the predominant distribution of PDE5 in the lungs. It is believed, therefore, that the effect of DA-8159 on PH is mediated by augmenting pulmonary arterial relaxation through elevated cGMP levels. These results are comparable to those seen with other PDE5 inhibitors such as E-4010 and sildenafil. 2, 13 With regards to myocardial morphology, right ventricle samples from MCT-treated animals showed the presence of focal myocyte degeneration (data not shown) and fibrosis. In contrast, there were no histopathological abnormalities including fibrotic changes in the group treated with DA-8159 5 mg/kg. This demonstrates that the beneficial effects of DA-8159 were also observed in respect to morphological abnormalities.
In summary, these results show that DA-8159 markedly attenuates the compensatory development of right ventricular hypertrophy in MCT-induced PH. The beneficial effects were observed with respect to a variety of indices, including reduced right ventricular hypertrophy, reduced pulmonary artery medial wall thickness, body weight gains and the attenuation of morphological changes. We conclude therefore, that DA-8159 might have beneficial effects on PH, but its safety and efficacy in humans remains to be studied.
